AC
ABBV icon

AlphaCore Capital’s AbbVie ABBV Stock Holding History

AlphaCore Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
45,476
+10,951
+32% +$2.36M 0.21% 99
2026
Q1 		$7.51M Buy
34,525
+1,097
+3% +$243K 0.18% 106
2025
Q4 		$7.64M Buy
33,428
+2,877
+9% +$655K 0.17% 122
2025
Q3 		$7.07M Buy
30,551
+2,522
+9% +$514K 0.24% 86
2025
Q2 		$5.2M Buy
28,029
+4,182
+18% +$777K 0.2% 100
2025
Q1 		$5M Buy
23,847
+4,338
+22% +$843K 0.42% 47
2024
Q4 		$3.47M Buy
19,509
+182
+0.9% +$33.5K 0.75% 22
2024
Q3 		$3.82M Buy
19,327
+42
+0.2% +$7.84K 0.86% 19
2024
Q2 		$3.31M Sell
19,285
-385
-2% -$63.8K 0.8% 22
2024
Q1 		$3.58M Buy
19,670
+3
+0% +$517 0.95% 20
2023
Q4 		$3.05M Buy
19,667
+662
+3% +$96.5K 0.45% 42
2023
Q3 		$2.83M Buy
19,005
+306
+2% +$44.9K 0.45% 43
2023
Q2 		$2.52M Buy
+18,699
New +$2.74M 0.4% 53
2020
Q2 		– Sell
-149
Closed -$11K – 71
2020
Q1 		$11K Buy
+149
New +$12.7K 0.01% 201

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

AlphaCore Capital's ABBV Position: Q2 2026 in Review

AlphaCore Capital increased its AbbVie (ABBV) stake by 32% in Q2 2026, buying an estimated $2.36M and bringing the position to 45,476 shares worth $11.4M. The position accounts for 0.21% of the portfolio, ranked #99.

AlphaCore Capital first reported a position in ABBV in Q1 2020 and has held it in 14 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • AlphaCore Capital held 45,476 shares of AbbVie worth $11.4M as of Q2 2026.
  • AlphaCore Capital bought 10,951 AbbVie shares in Q2 2026, an estimated $2.36M.
  • AbbVie made up 0.21% of AlphaCore Capital's portfolio in Q2 2026, its #99 holding.
  • AlphaCore Capital first reported a position in AbbVie in Q1 2020 and has held it in 14 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.